CBG, or cannabigerol, is the "princess of pot" in terms of being the child of the queen of cannabinoids, CBGA. It delivers a significant amount of medicinal benefit. This non-psychoactive cannabinoid has been found to be a pain killer, an anti-cancer agent, and—along with CBD and CBC, an anti-depressant.
It is, in addition to THCV, CBDV, and CBC, among the small subset of bone stimulants in this group. It is present in large quantities in many types of hemp, the variety of cannabis almost completely lacking THC. (Legally, in North America, a strain of cannabis can contain no more than 0.3 percent THC to be defined as hemp.)
Another potential advantage of CBG is that it seems to counter the paranoia that is delivered by some THC-rich strains of cannabis. In this respect, it conveys the opposite effect of myrcene and CBC. Strains high in CBG have been found to be effective in treating glaucoma due to how this cannabinoid helps decrease pressure within the eye and expedites the drainage of fluids.
The value of CBG is being recognized by the cannabis breeding and cultivation communities, which are responding with new strains that are high in CBG, which is typically present in only small quantities within most varieties of cannabis. One example is TGA Genetics Subcool Seeds, which has created a cultivar called Mickey Kush that is rich in both THC and CBG.
Why Is So Little Understood?
These chemical processes become even more complex when one considers that THC sometimes degrades into CBN, which in many respects is simply stale THC. Likewise, CBCA can result in CBLA, a cannabinoid about which very little is know other than that it is an anti-inflammatory.
Given the stunning medical value that has been uncovered to date by only limited research studies and anecdotal reports from patients and caregivers, the fact that research is being discouraged in the United States is a travesty to tens of millions of patients suffering with dozens of diseases related to or resulting in pain, nausea, inflammation, or depression.
Copyright © 2017-2020 by Curt Robbins. All Rights Reserved.
In the big picture, humans are relatively ignorant of the cannabinoids and terpenes in this herb, including their delicate interplay. Until cannabis is removed from Schedule I under the Controlled Substances Act, little research and no human trials will occur in the United States. This is despite the fact that international studies and volumes of patient testimonials indicate that cannabis is a powerful, holistic, and versatile medicine—for both physical and psychological diseases—that carry few or no negative side effects.
"In the big picture, humans are relatively ignorant of the cannabinoids and terpenes in this herb, including their delicate interplay."
Under Schedule I, however, cannabis is considered to have zero medical value and to be dangerous and highly addictive, where it resides with drugs like bath salts and heroin.
In fact, both methamphetamines and cocaine reside in less-restrictive Schedule II, meaning they can be prescribed by a physician and are supposedly less addictive than cannabis. Until Congress and more corporate and policy leaders act to change this situation (a logical solution would be moving cannabis to Schedule III), consumers and patients will continue to suffer under ambiguity and a lack of scientific fact.
All text and photos, unless otherwise noted, Copyright © 2020 Curt Robbins. All Rights Reserved.
About the Author
Curt Robbins is a technical writer, instructional designer, and lecturer who has been developing science-based educational and training content for Fortune 200 enterprises for more than 30 years. His clients have included Federal Express, Microsoft, Sun Microsystems, Northrop Grumman, National City Bank, Strainprint Technologies Ltd., the J.M. Smucker Company, and USAA.
Robbins has developed more than 600 educational articles regarding hemp and its various health components, including terpenes, cannabinoids, and the human endocannabinoid system for clients in the U.S., Canada, and Israel. His latest white paper, CBG: The Mother of Cannabinoids, is an evidence-based 50-page deep dive into the biochemistry of the hemp-derived phytocannabinoid cannabigerol that features 60 peer-reviewed research study citations.